Novo Nordisk (NYSE:NVO) Shares Gain 4%
The move was off news from Roche which Street Insider cited saying Roche's CT-996 obesity pill had rates of nausea and GERD as high as 86% in a small study, though the side effects were milder in a group that had their doses boosted more slowly. Simply put: Obesity Pill’s Side Effects Blunted by Gradual Dosing.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads.
Is NVO truely undervalued?
With NVO making headlines, investors are asking: Is it truly valued fairly? InvestingPro's advanced AI algorithms have analyzed NVO alongside thousands of other stocks to uncover hidden gems with massive upside. And guess what? NVO wasn't at the top of the list.
Unlock ProPicks AI